Make the move with resources for healthcare professionals

    Salix has a suite of services dedicated to assisting you and your practice in managing
    your patients:

    • On formulary coverage for more than 90% of total commercially insured patients,* APRISO may be an affordable choice
    • The APRISO Savings Card can help most of your eligible patients save on every prescription—$0 co-pay or out-of-pocket expense on the first APRISO Rx and $10 co-pays or out-of-pocket expense on all future Rx's for the duration of the program
    • Coverage includes preferred status on many national plans

    We want to help ensure that your patients have access to the Salix medication you prescribe. Our team of Access Coordinators can work with you every step of the way to:

    • Determine a patient's insurance coverage
    • Connect patients with appropriate cost-share assistance resources
    • Provide prior authorization support (and monitor PA status)
    • Determine eligibility for the APRISO Patient Assistance Program
    • Identify alternate insurance coverage, if appropriate
    • Provide payer-specific forms and template letters to be completed by your office, if necessary, to help support the coverage process
    Download the APRISO Reimbursement Helpline Form

    *

    Fingertip Formulary, November 2016.

    Maximum benefit of $110 off the first use; maximum benefit of $100 of each subsequent use. Federally insured patients are not eligible. Please see full eligibility criteria, terms and conditions contained on the reverse of the Instant Savings Card or on the APRISO patient website located at www.aprisorx.com.


    INDICATION

    APRISO® (mesalamine) extended-release capsules are indicated for the maintenance of remission of ulcerative colitis (UC) in patients 18 years of age and older.

    IMPORTANT SAFETY INFORMATION—APRISO extended-release capsules

    • APRISO extended-release capsules are contraindicated in patients with hypersensitivity to salicylates or aminosalicylates, or to any of the components of APRISO capsules.
    • Renal impairment, including minimal change nephropathy, acute and chronic interstitial nephritis, and, rarely, renal failure, has been reported in patients given products such as APRISO that contain mesalamine or are converted to mesalamine. It is recommended that patients have an evaluation of renal function prior to initiation of APRISO therapy and periodically while on therapy. Exercise caution when using APRISO in patients with known renal dysfunction or a history of renal disease.
    • Mesalamine has been associated with an acute intolerance syndrome that may be difficult to distinguish from a flare of inflammatory bowel disease. Symptoms include cramping, acute abdominal pain and bloody diarrhea, sometimes fever, headache, and rash. If acute intolerance syndrome is suspected, promptly discontinue treatment with APRISO.
    • There have been reports of hepatic failure in patients with pre-existing liver disease who have been administered mesalamine. Caution should be exercised when administering APRISO to patients with liver disease.
    • In clinical studies, the most common adverse reactions (occurring in ≥3% of APRISO patients and at a greater rate than placebo) were headache (11%), diarrhea (8%), upper abdominal pain (5%), nausea (4%), nasopharyngitis (4%), influenza and influenza-like illness (4%), and sinusitis (3%).
    • Because dissolution of the coating of APRISO granules depends on pH, APRISO should not be co-administered with antacids.
    • Because of the potential for blood dyscrasias in patients 65 years and older, caution should be taken to closely monitor blood cell counts during mesalamine therapy in these patients.
    • Inform patients with phenylketonuria (PKU) or their caregivers that each APRISO capsule contains aspartame equivalent to 0.56 mg of phenylalanine, so that the recommended adult dosing provides an equivalent of 2.24 mg of phenylalanine per day.

    To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-508-0024 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

    Please click here for full Prescribing Information for APRISO extended-release capsules.

    For product information, adverse event reports, and product complaint reports, please contact:

    Salix Product Information Call Center
    Phone: 1-800-508-0024
    Fax: 1-510-595-8183
    Email: salixmc@dlss.com